Addex Convenes Annual General Meeting 2024
June 05 2024 - 12:00AM
Ad Hoc Announcement Pursuant to Art. 53
LR
Geneva, Switzerland, June 5,
2024 - Addex Therapeutics (SIX: ADXN and
Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused
on developing a portfolio of novel small molecule allosteric
modulators for neurological disorders, announced today that its
2024 Annual General Meeting will take place on Friday June 28,
2024, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9,
1202 Geneva (doors open at 10:30 am).
Agenda
1. Approval of the Annual
Report, the Annual Financial Statements and the Consolidated
Financial Statements for the business year
20232. Consultative vote on the Compensation
Report for the business year 20233. Appropriation
of the results4. Discharge of the members of the
Board of Directors and of the Executive
Management5. Re-elections of the members of the
Board of Directors and re-election of the Chairman of the Board of
Directors5.1. Re-election of
Vincent Lawton as member and Chairman of the Board of
Directors5.2. Re-election of
Raymond Hill as member of the Board of
Directors5.3. Re-election of
Timothy Dyer as member of the Board of
Directors5.4. Re-election of
Roger Mills as member of the Board of
Directors5.5. Re-election of
Jake Nunn as member of the Board of
Directors5.6. Re-election of
Isaac Manke as member of the Board of Directors
6. Re-elections of the members
of the Compensation
Committee6.1. Re-election of
Vincent Lawton as member of the Compensation
Committee6.2. Re-election of
Raymond Hill as member of the Compensation Committee
7. Re-election of the
Auditors8. Re-election of the Independent Voting
Rights Representative9. Amendments to the Articles
of Association9.1. Increase of
the capital band (article 3b of the Articles of
Association)9.2. Increase of the
conditional share capital (article 3c of the Articles of
Association)9.3. Other
amendments to the Articles of Association related to the revised
corporate law9.3.1. Matters
related to shareholders and general
meetings9.3.1.1. Powers of
the shareholders meeting (article 8 of the Articles of
Association)9.3.1.2. Ordinary
and Extraordinary Meeting of shareholders (article 9 of Articles of
Association)9.3.1.3. Agenda
(article 11 of Articles of
Association) 9.3.2.
Attributions of the Board of Directors (article 19 of Articles of
Association)9.3.3. Compensation
and Mandates Outside of the
Group9.3.3.4. Additional
amounts in case of changes in the Executive Management (article 28
of Articles of
Association)9.3.3.5. Agreements
with members of the Board of Directors and of the Executive
Management (article 29 of the Articles of
Association)9.3.3.6. Mandates
Outside the Group (article 31 of the Articles of Association)
10. Approval of the compensation of the members of
the Board of Directors and of the Executive
Management10.1. Compensation of
the members of the Board of
Directors10.2. Compensation of
the members of the Executive Management
11. MiscellaneousThe full
invitation to the AGM 2024 may be found in the General Meetings
section of the Company’s website here.
About Addex:Addex Therapeutics is a
clinical-stage biopharmaceutical company focused on developing a
portfolio of novel small molecule allosteric modulators for
neurological disorders. Addex’s lead drug candidate, ADX71149
(mGlu2 positive allosteric modulator or PAM), developed in
collaboration with Janssen Pharmaceuticals Inc., has recently
completed a Phase 2 clinical study for the treatment of epilepsy.
The Company’s second clinical program, dipraglurant (mGlu5 negative
allosteric modulator or NAM), is under evaluation for future
development in dyskinesia associated with Parkinson’s disease and
post-stroke/TBI recovery. Addex partnership with Indivior on GABAB
PAM is advancing multiple drug candidates through clinical
candidate selection for substance use disorder. Under the agreement
with Indivior, Addex is advancing an independent GABAB PAM program
for chronic cough through clinical candidate selection. Addex also
holds a 20% share in a private company, Neurosterix LLC which is
advancing a portfolio of allosteric modulator programs including
M4PAM for schizophrenia, mGlu7NAM for stress related disorders and
mGlu2NAM for mild neurocognitive disorders. Addex shares are listed
on the SIX Swiss Exchange and American Depositary Shares
representing its shares are listed on the NASDAQ Capital Market,
and trade under the ticker symbol “ADXN” on each exchange. For more
information, visit www.addextherapeutics.com
Contacts:
| Tim DyerChief
Executive OfficerTelephone: +41 22 884 15
55PR@addextherapeutics.com |
Mike
SinclairPartner, Halsin Partners+44 (0)7968
022075msinclair@halsin.com |
Addex Forward Looking Statements:This press
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, as amended,
including statements about the intended use of proceeds of the
offering. The words “may,” “will,” “could,” “would,” “should,”
“expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,”
“predict,” “project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release, are based on management's current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, uncertainties related to market conditions. These and
other risks and uncertainties are described in greater detail in
the section entitled “Risk Factors” in Addex Therapeutics’ Annual
Report on Form 20-F for the year ended December 31, 2023, as filed
with the SEC on April 18, 2024, the final prospectus supplement and
accompanying prospectus and other filings that Addex Therapeutics
may make with the SEC in the future. Any forward-looking statements
contained in this press release represent Addex Therapeutics’ views
only as of the date hereof and should not be relied upon as
representing its views as of any subsequent date. Addex
Therapeutics explicitly disclaims any obligation to update any
forward-looking statements.
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Jan 2025 to Feb 2025
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Feb 2024 to Feb 2025
